Stampidine as a potent epigenetic silencer of host HIV dependency factor genes in HIV-infected cells

Journal of AIDS and Clinical Research

Volumn 3, Issue 4, 2012, Pages

  Qazi, Sanjive ^a,b,c   Uckun, Fatih M ^b,c,d  

^a GUSTAVUS ADOLPHUS COLLEGE   (United States)

^b PARKER HUGHES INSTITUTE   (United States)

^c CHILDREN S HOSPITAL LOS ANGELES   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84879834264     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.1000147     Document Type: Article

References (34)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
2. Richman DD, Margolis DM, Delaney M, Greene WC, Hazuda D, et al. (2009) The challenge of finding a cure for HIV infection. Science 323: 1304-1307.
3. Uckun FM (2006) Unmet challenges in HIV therapy and potential of stampidine. Arzneimittelforschung 56: 117-120.
4. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, et al. (2010) Update of the Drug Resistance Mutations in HIV-1: December 2010. Top HIV Med 18: 156-163.
5. Kantor R, Katzenstein DA, Efron B, Carvalho AP, Wynhoven B, et al. (2005) Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration. PLoS Med 2: e112.
6. Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, et al. (2005) HIV protease and reverse transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug resistance surveillance. J Infect Dis 192: 456-465.
7. Shafer RW, Kantor R, Gonzales MJ (2000) The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Rev 2: 211-228.
8. Kelesidis T, Landovitz RJ (2011) Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep 8: 94-103.
9. Lampe MA, Smith DK, Anderson GJ, Edwards AE, Nesheim SR (2011) Achieving safe conception in HIV-discordant couples: the potential role of oral preexposure prophylaxis (PrEP) in the United States. Am J Obstet Gynecol 204: 488. e1-8.
10. Mayer KH, Venkatesh KK (2010) Chemoprophylaxis for HIV prevention: new opportunities and new questions. J Acquir Immune Defic Syndr 2: S122-127.
11. Das K, Bandwar RP, White KL, Feng JY, Sarafianos SG, et al. (2009) Structural basis for the role of the K65R mutation in HIV-1 reverse transcriptase polymerization, excision antagonism, and tenofovir resistance. J Biol Chem 284: 35092-35100.
12. Hurt CB, Eron JJ Jr, Cohen MS (2011) Pre-Exposure Prophylaxis and Antiretroviral Resistance: HIV Prevention at a Cost? Clin Infect Dis 53: 1265-1270.
13. White KL, Chen JM, Margot NA, Wrin T, Petropoulos CJ, et al. (2004) Molecular mechanisms of tenofovir resistance conferred by human immunodeficiency virus type 1 reverse transcriptase containing a diserine insertion after residue 69 and multiple thymidine analog-associated mutations. Antimicrob Agents Chemother 48: 992-1003.
14. Brass AL, Dykxhoorn DM, Benita Y, Yan N, Engelman A, et al. (2008) Identification of host proteins required for HIV infection through a functional genomic screen. Science 319: 921-926.
15. Bushman FD, Malani N, Fernandes J, D'Orso I, Cagney G, et al. (2009) Host cell factors in HIV replication: meta-analysis of genome-wide studies. PLoS Pathog 5: e1000437.
16. König R, Stertz S, Zhou Y, Inoue A, Hoffmann HH, et al. (2010) Human host factors required for influenza virus replication. Nature 463: 813-817.
17. Konig R, Zhou Y, Elleder D, Diamond TL, Bonamy GM, et al. (2008) Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replication. Cell 135: 49-60.
18. Zhou H, Xu M, Huang Q, Gates AT, Zhang XD, et al. (2008) Genome-scale RNAi screen for host factors required for HIV replication. Cell Host Microbe 4: 495-504.
19. Uckun FM (2006) Aryl phosphate derivatives of d4T having activity against resistant HIV strains. US Patent No. 7144874.
20. Johnston E, Dupnik KM, Gonzales MJ, Winters MA, Rhee SY, et al. (2005) Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations. AIDS 19: 731-733.
21. Qazi S, Soiseth NL, Uckun FM (2010) Early detection of subtype-specific HIV-1 infection using transcriptomes from host cell responses. EJBS 2: 65-79.
22. Qazi S, Uckun FM (2010) Gene expression profiles of infant acute lymphoblastic leukaemia and its prognostically distinct subsets. Br J Haematol 149: 865-873.
23. Uckun FM, Goodman P, Ma H, Dibirdik I, Qazi S (2010) CD22 Exon 12 Deletion as a Novel Pathogenic Mechanism of Human B-Precursor Leukemia. Proc Natl Acad Sci U S A 107: 16852-16857.
24. Uckun FM, Qazi S, Ma H, Tuel-Ahlgren L, Ozer Z (2010) STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc Natl Acad Sci U S A 107: 2902-2907.
25. Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, et al. (2010) Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res 20: 440-446.
26. Weisenberger DJ, Den Berg DV, Pan F, Berman BP, Laird PW (2008) Comprehensive DNA methylation analysis on the Illumina Infinium assay platform. Technical report. Illumina, Inc; San Diego.
27. Du P, Zhang X, Huang CC, Jafari N, Kibbe WA, et al. (2010) Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis. BMC Bioinformatics 11: 587.
28. Uckun FM, Pendergrass S, Venkatachalam TK, Qazi S, Richman D (2002) Stampidine is a potent inhibitor of zidovudine and nucleoside analog reverse transcriptase inhibitor-resistant primary clinical HIV-1 isolates with thymidine analog mutations. Antimicrob Agents Chemother 46: 3613-3616.
29. Uckun FM, Qazi S, Pendergrass S, Lisowski E, Waurzyniak B, et al. (2002) In vivo toxicity, pharmacokinetics, and anti-HIV activity of stavudine-5'-(p-bromo phenyl methoxyalaninyl phosphate) (stampidine) in mice. Antimicrob Agents Chemother 46: 3428-3436.
30. Uckun FM, Waurzyniak B, Tibbles H, Venkatachalam TK, Erbeck D (2006) In vivo pharmacokinetics and toxicity profile of the anti-HIV agent stampidine in dogs and feline immunodeficiency virus-infected cats. Arzneimittelforschung 56: 176-192.
31. Uckun FM, Chen CL, Samuel P, Pendergrass S, Venkatachalam TK, et al. (2003) In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected cats. Antimicrob Agents Chemother 47: 1233-1240.
32. DuMez D, Venkatachalam TK, Uckun FM (2006) Large-scale synthesis and formulation of GMP-grade stampidine, a new anti-HIV agent. Arzneimittelforschung 56: 136-151.
33. Cahn P, Rolon MJ, Gun AM, Ferrari I, Dibirdik I, et al. (2012) Preclinical and First-In-Human Phase I Clinical Evaluation of Stampidine, A Potent Anti-HIV Pharmaceutical Drug Candidate. J AIDS Clinic Res 3: 1-8.
34. Hagemann S, Heil O, Lyko F, Brueckner B (2011) Azacytidine and Decitabine Induce Gene-Specific and Non-Random DNA Demethylation in Human Cancer Cell Lines. PLoS One 6: e17388.